24 Jan

Analysts’ Recommendations for Arrowhead and Its Peers

WRITTEN BY Kenneth Smith

Company overview

Incorporated in Delaware, Arrowhead Pharmaceuticals (ARWR) is focused on developing medicines for treating intractable diseases by silencing the genes that cause them. The therapies developed by Arrowhead make use of a broad portfolio of RNA chemistries and efficient modes of delivery to trigger an RNA interference mechanism that induces the rapid and durable knockdown of the target genes.

RNA interference or (RNAi) is a mechanism that inhibits the expression of a specific gene. Through this inhibition of a specific gene, the production of a specific protein can be stopped.

Analysts’ Recommendations for Arrowhead and Its Peers

The discoverers of RNAi were awarded a Nobel Prize in 2006 for this work. Their discovery is deemed to be one of the most important recent discoveries in life sciences, and it has the potential to transform medicine.

Analysts’ recommendations

Of the five analysts covering Arrowhead Pharmaceuticals in January 2018, two have given the stock a “buy” or higher rating, while three have given it a “hold” rating. The mean rating for the stock is 2.4, and its target price is $3.5.

Arrowhead Pharmaceuticals makes up ~0.22% of the Vanguard Global ex-U.S. Real Estate ETF’s (VNQI) total portfolio holdings.

Peers’ ratings

Of the 29 analysts covering Gilead Sciences (GILD) in January 2018, 15 have given the stock a “buy” or higher rating, while the remaining 14 have given the stock a “hold” rating. The mean rating for the stock is 2.34, and it has a target price of $86.13.

All four of the analysts covering Ignyta (RXDX) in January 2018 have given the stock a “hold” rating. The mean rating for the stock is 3, and it has a target price of $28.

All eight of the analysts covering Loxo Oncology (LOXO) in January 2018 have given the stock a “buy” or higher rating. The mean rating for the stock is 1.38, and its target price is $11.83.

In the next article, we’ll take a look at Arrowhead Pharmaceuticals’ TRiM platform.

Latest articles

Since my last article about Nvidia (NVDA), the stock has risen from $196.86 to $208.57. I expect a further rise after today's earnings results.

TJX Companies (TJX) is scheduled to announce its fiscal 2020 third-quarter earnings results on November 19. Its third quarter ended on November 2.

AT&T stock is currently trending downward in today’s trading session. It’s down about 1% as of 11:52 AM ET. The stock fell after HSBC downgraded its rating.

Canopy Growth reported its second-quarter earnings results today. It's already down 16.07% on the day and is trading at 20.52 Canadian dollars on the TSE.

The EIA released its inventory report at 10:30 AM ET. WTI crude oil prices rose around 0.4% at 11:31 AM ET from their last closing level.

Alibaba stock has seen turbulence throughout the year, as the US and China have often been at odds. It fell around 2.4% on November 13.